RT Journal Article
SR Electronic
T1 Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update
JF Annals of the Rheumatic Diseases
JO Ann Rheum Dis
FD BMJ Publishing Group Ltd and European League Against Rheumatism
SP 773
OP 787
DO 10.1136/ard-2022-222784
VO 82
IS 6
A1 Daniel Aletaha
A1 Andreas Kerschbaumer
A1 Kastriot Kastrati
A1 Christian Dejaco
A1 Maxime Dougados
A1 Iain B McInnes
A1 Naveed Sattar
A1 Tanja A Stamm
A1 Tsutomu Takeuchi
A1 Michael Trauner
A1 Désirée van der Heijde
A1 Marieke Voshaar
A1 Kevin L Winthrop
A1 Angelo Ravelli
A1 Neil Betteridge
A1 Gerd-Rüdiger R Burmester
A1 Johannes WJ Bijlsma
A1 Vivian Bykerk
A1 Roberto Caporali
A1 Ernest H Choy
A1 Catalin Codreanu
A1 Bernard Combe
A1 Mary K Crow
A1 Maarten de Wit
A1 Paul Emery
A1 Roy M Fleischmann
A1 Cem Gabay
A1 Merete Lund Hetland
A1 Kimme L Hyrich
A1 Annamaria Iagnocco
A1 John D Isaacs
A1 Joel M Kremer
A1 Xavier Mariette
A1 Peter A Merkel
A1 Eduardo F Mysler
A1 Peter Nash
A1 Michael T Nurmohamed
A1 Karel Pavelka
A1 Gyula Poor
A1 Andrea Rubbert-Roth
A1 Hendrik Schulze-Koops
A1 Anja Strangfeld
A1 Yoshiya Tanaka
A1 Josef S Smolen
YR 2023
UL http://ard.bmj.com/content/82/6/773.abstract
AB Background Targeting interleukin (IL)-6 has become a major therapeutic strategy in the treatment of immune-mediated inflammatory disease. Interference with the IL-6 pathway can be directed at the specific receptor using anti-IL-6Rα antibodies or by directly inhibiting the IL-6 cytokine. This paper is an update of a previous consensus document, based on most recent evidence and expert opinion, that aims to inform on the medical use of interfering with the IL-6 pathway.Methods A systematic literature research was performed that focused on IL-6-pathway inhibitors in inflammatory diseases. Evidence was put in context by a large group of international experts and patients in a subsequent consensus process. All were involved in formulating the consensus statements, and in the preparation of this document.Results The consensus process covered relevant aspects of dosing and populations for different indications of IL-6 pathway inhibitors that are approved across the world, including rheumatoid arthritis, polyarticular-course and systemic juvenile idiopathic arthritis, giant cell arteritis, Takayasu arteritis, adult-onset Still’s disease, Castleman’s disease, chimeric antigen receptor-T-cell-induced cytokine release syndrome, neuromyelitis optica spectrum disorder and severe COVID-19. Also addressed were other clinical aspects of the use of IL-6 pathway inhibitors, including pretreatment screening, safety, contraindications and monitoring.Conclusions The document provides a comprehensive consensus on the use of IL-6 inhibition to treat inflammatory disorders to inform healthcare professionals (including researchers), patients, administrators and payers.